Switching from a biologic to a biosimilar did not affect safety or efficacy in a clinical trial of a rheumatoid arthritis biosimilar for etanercept (Enbrel, Amgen), shows a new study.
Gregory M. Weiss, M.D.
A second study published in May on the safety and efficacy of biosimilars, shows that switching rheumatoid arthritis patients from etanercept (Enbrel, Amgen) to its biosimilar etanercept-szzs (Erelzi, Sandoz), does not affect efficacy, safety or immunogenicity of etanercept.
Remission is unlikely in non-radiographic axial spondyloarthritis without biologic therapy. Adding certolizumab to background therapy can lead to significant improvements in disease activity compared to placebo, researchers find.
In a recent edition of Frontiers in Immunology, Dr. Walter Maksymowych, University of Alberta, reviews the use of biomarkers for diagnosis and prognosis in axial spondyloarthritis. Learn more in this summary.
A review article confirms low adherence and persistence rates for medication compliance in rheumatoid arthritis, psoriasis and psoriatic arthritis. Patients with higher adherence rates had better outcomes.
Serious infections are low, but herpes zoster surpasses expectations, review article shows.
Patient access to biologic therapies is an issue throughout the European Union where the authors of a review article zero in on “why.” Access issues, they find, have a lot in common with access issues here in the U.S.
Rheumatoid arthritis, psoriasis and psoriatic arthritis patients have consistently low levels of biologic adherence and persistence. How can patient compliance be improved? Lower out-of-pocket costs, utilize specialty pharmacies and improve patient education.
Delays in diagnosing axSpA are troubling, write the authors of a report in the journal Rheumatology. Delays of up to 10 years have been reported. Not all physicians may be familiar with the signs and symptoms of axSpA.
Physiotherapy, exercise and pain medications should be part of the treatment plan to improve the quality of life of patients suffering from stiffness associated with axial spondyloarthritis.